L., Rrth, R., Jhund, P
Figure 2 Discussion Accumulating evidence suggests that the relationship between GLP-1 RAs and the gut microbiome may extend beyond a simple secondary consequence of weight loss or glycemic improvement, although the relative contribution of direct pharmacological effects versus indirect metabolic changes remains incompletely defined
These forms are designated by the prefixes "L" and "D"
Salzer MC, Lafzi A, Berenguer-Llergo A, Youssif C, Castellanos A, Solanas G, et al
Patients frequently report discovering a newfound relationship with food, enabling sustainable lifestyle changes
The Bottom Line : Combining CBD and GLP-1 medications is generally low risk for drug-metabolism conflicts, but the overlap in slowed gastric emptying and GI side effects makes a low starting dose, careful symptom tracking, and a conversation with your prescriber the right approach